Feasibility and Safety of Dose-Adjusted Apixaban for Treating Cancer-Associated Blood Clots and Low Platelet Counts

What this Trial Is About

Researchers are evaluating the feasibility and safety of a new dose-adjusted form of apixaban for managing people with cancer-associated blood clots and low platelet counts. This early-phase study focuses on whether this treatment can be safely used in this group and aims to see if it reduces bleeding episodes. Apixaban is already FDA-approved for other blood clot conditions but has not been studied in cancer patients with thrombocytopenia before. Participants will take apixaban tablets by mouth twice daily for 90 days, with doses adjusted based on platelet counts and other factors. The study includes a baseline assessment before treatment, an off-treatment visit one week after the last dose, and a follow-up visit six weeks later. About 30 people are expected to join this research. During the study, participants will have clinic visits and blood tests to monitor their platelet levels and overall health. Researchers will track how well participants stick to the medication schedule and platelet monitoring plan, as well as record any bleeding events and recurrent blood clots. The study treatment lasts 90 days, followed by a 6-week observation period after stopping the drug to ensure ongoing safety and collect outcome data.

Apixaban in Thrombocytopenia